Mark Manfredi, Ikena Oncology CEO
Ikena inks small cash grab in all-stock deal for Pionyr to take cancer drug on Hippo pathway
Ikena Oncology said it added about $43 million to its runway after making an all-stock acquisition of the private startup Pionyr …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
